CIPLA

profit crashed 55% yesterday. The stock went up 8%. That's not a mistake. That's the market reading the story behind the headline. Here's what actually happened Q4 PAT: ₹555 Cr — down 55% YoY Revenue: ₹6,541 Cr — down 2.8% Ugly on the surface. But dig one level deeper → India domestic business grew 15% → Full-year revenue hit an all-time high of ₹28,163 Cr → Management has guided for EBITDA margins of 18.5–20% in FY27, with sequential improvement quarter-on-quarter driven by new launches → The US business is targeting a $1 billion run rate by end of FY27, backed by 4 respiratory launches and a major peptide launch → Cipla just got USFDA approval for the first AB-rated generic of Ventolin HFA — a first-to-market opportunity in the US respiratory segment MoneyWorks4me + 4 The Q4 miss was almost entirely driven by US headwinds and higher R&D spend. Both are temporary. The pipeline is real. JM Financial upgraded the stock to BUY with a target of ₹1,546, citing improving US product launch visibility and earnings recovery from H2 FY27. ICICIdirect The lesson here isn't about Cipla specifically. It's about how the market prices the future, not the last quarter. Bad numbers + strong guidance + a credible pipeline = institutions buy while retail panics. The stock is already up 23% from its 52-week low of ₹1,165 in just two sessions. The ones waiting for "good results" to buy? They already missed the move